APCCC 2022 | Future developments in the field of radionuclides

Ken Herrmann, MD, MBA, Universitätsklinikum Essen, Essen, Germany talks on the key areas of development in the field of radionuclides for prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) treatment. Prof. Herrmann discusses the SPLASH (NCT04647526) and ECLIPSE (NCT05204927) trials and the recent FDA approval of Lutetium-177 PSMA. Moreover, Prof. Herrmann comments on the development of this technology beyond the prostate to other types of solid tumours. This interview took place at the APCCC 2022 conference, held in Lugano, Switzerland.